Close



Dec 20, 2020 07:00PM
Dec 7, 2020 01:32PM
Dec 7, 2020 01:30PM
Nov 20, 2020 10:30AM
Nov 20, 2020 10:30AM
Nov 13, 2020 06:12AM
Nov 12, 2020 07:06PM Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
Nov 2, 2020 05:03PM
Nov 2, 2020 04:05PM
Nov 2, 2020 04:03PM
Nov 2, 2020 04:01PM
Aug 4, 2020 07:00AM
Jun 12, 2020 07:03AM
Jun 12, 2020 07:00AM Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting
Jun 9, 2020 09:03AM
Jun 9, 2020 09:00AM
May 28, 2020 04:26PM
May 28, 2020 04:05PM
May 26, 2020 07:00AM
May 20, 2020 08:07AM
May 20, 2020 08:00AM Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
May 5, 2020 08:30AM
May 5, 2020 07:00AM
Apr 29, 2020 01:58PM
Apr 20, 2020 07:06AM
Apr 20, 2020 07:00AM
Apr 7, 2020 07:04AM
Apr 7, 2020 07:00AM Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19
Feb 19, 2020 08:10AM
Feb 19, 2020 08:00AM
Jul 3, 2019 10:53AM
May 9, 2019 07:02AM
May 9, 2019 07:02AM
Mar 15, 2019 09:25AM
Mar 15, 2019 09:05AM Karyopharm Therapeutics (KPTI) PDUFA Delay Signals FDA Receptivity - RBC
Mar 14, 2019 04:59PM
Mar 14, 2019 04:57PM
Feb 28, 2019 07:00AM
Feb 28, 2019 07:00AM
Feb 27, 2019 06:37AM
Feb 27, 2019 06:24AM
Feb 26, 2019 05:47PM Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
Feb 26, 2019 05:47PM
Feb 26, 2019 12:33PM
Feb 26, 2019 12:31PM
Feb 26, 2019 12:31PM
Feb 7, 2019 07:48AM
Feb 7, 2019 07:00AM
Feb 7, 2019 07:00AM Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
Jan 8, 2019 12:21PM

12,349 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All